Our History

Search initiated 2008

Closeup of two hands with gloves holding a test container

About us » Our history

With chronic pain treatment focus

PharmNovo was founded in 2008 by Bengt von Mentzer after 27 years as a drug discovery group leader for Astra Zeneca. With a focus on chronic pain treatment PharmNovo started to develop novel delta opioid receptor agonists.

With chemist, Ingemar Starke, new chemistry was developed and we identified novel potent, selective and biased DOR agonists (a new concept in pharmacology at the time). In 2010, David Kendall, Professor of Pharmacology at Nottingham University UK joined the company part time and became full time CSO in 2015.

In 2016 a collaboration with Professor Eamon Kelly’s research group at the University of Bristol was started with the aim of studying delta opioid receptor biased agonism. This collaboration has been supported by grants from the UK Medical Research Council.

Pre-clinical studies were completed for the candidate compound PN6047 with very promising results and at the end of the year PharmNovo was granted a patent in the USA.

2008 Q1

AZ project

AstraZeneca granted PharmNovo AB a project application of novel delta agonists including 105 molecules, data and compound. The compounds and patent application were abandoned 2012 following invention of our own molecules.



VGR (Västra Götaland) fund PharmNovo with 0.4 million SEK.



VGR fund PharmNovo with 0.45 million SEK.



Two candidate selective and biased delta agonists chosen, PN6047 and PN6053.


Angel Investor

Angel Investor funds PharmNovo with £200.000 + £100.000 on two occasions, 2014 and 2015.


CD patent applications

Patent applications with PN6047, PN6053 and others.


CD patent applications withdrawn

Both patents withdrawn from Swedish Patent Office and resubmitted as PCT applications and further 2016 as European patent application and 2017 as world wide patent application.


MRC grant approved

Medical Research Council grant for three years approved with Eamonn Kelly, U. of Bristol,.


European Patent demand defended and approved

European patent demand defended.


Capital investment and US patent received

New Capital investments in Q3 to finance patent costs and finalize pre-clinical studies. US patent granted for PN6047 in Q4 2018 and European patent in final approval process.

2019 Q1

Complete toxicology plan

A synthesis method for large-scale production of PN6047was developed in Q1 and following that pre toxicology studies leading up to a complete regulatory toxicology plan were continued.

Latest news

View all
December 22, 2022

PharmNovo at Biostock

CEO Per von Mentzer presented PharmNovo at the BioStock - Connecting Innovation and Capital Life Science Fall Summit 2022. Watch his presentation addressing the large, unmet medical needs in the neuropathic pain market and learn more about our ongoing clinical trial and how we will achieve project milestones as PharmNovo moves forward.

Read more
December 22, 2022

Seasons Greetings 2022

The PharmNovo team would like to wish you a Merry Christmas and a Happy New Year!

Read more
October 11, 2022

Strengthening the team

PharmNovo has strengthened the team with a new experienced Project Manager and a Clinical Trial Manager

Read more
September 20, 2022

Good press in SvD

Read the story about PharmNovo and our drug candidate PN6047 for neurophatic pain and its ongoing phase I studies in Svenska Dagbladet.

Read more

By using this website, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.

Awesome 👌